ArticleGenetics in medicine : official journal of the American College of Medical Genetics2014
The economic value of personalized medicine tests: what we know and what we need to know.
Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review.Journal of managed care & specialty pharmacy · 2019Pooled it
- Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy.Expert review of pharmacoeconomics & outcomes research · 2018Pooled it
- Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.Genetics in medicine : official journal of the American College of Medical Genetics · 2016Pooled it
- Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.PloS one · 2016Pooled it
- Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Trial
- Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial.Genetics in medicine : official journal of the American College of Medical Genetics · 2018Trial
- Trial
- Beyond antimicrobials: a host-directed precision pharmacotherapy framework for septic shock.Frontiers in medicine · 2026Article
- Unveiling the Disparities in the Field of Precision Medicine: A Perspective.Health science reports · 2025Article
- How is Value Defined in Molecular Testing in Cancer? A Scoping Review.Applied health economics and health policy · 2025Article
- Pharmacogenomic profiling of variants affecting efficacy and toxicity of anti-infective medicines in a south Asian population from Sri Lanka.BMC infectious diseases · 2025Article
- Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Precision Medicine in Type 1 Diabetes.Journal of the Indian Institute of Science · 2023Review
- Economics and Precision Medicine.Handbook of experimental pharmacology · 2023Article
- Preferences for pharmacogenomic testing in polypharmacy patients: a discrete choice experiment.Personalized medicine · 2022Article
- Pharmacogenomic testing in paediatrics: Clinical implementation strategies.British journal of clinical pharmacology · 2022Review
- Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions.PharmacoEconomics · 2022Article
- When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review.Oncology and therapy · 2021Review
- The Interface of Therapeutics and Genomics in Cardiovascular Medicine.Cardiovascular drugs and therapy · 2021Review
- Cost-effectiveness of precision medicine: a scoping review.International journal of public health · 2019Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
purposeThere is uncertainty about when personalized medicine tests provide economic value. We assessed evidence on the economic value of personalized medicine tests and gaps in the evidence base.
methodsWe created a unique evidence base by linking data on published cost-utility analyses from the Tufts Cost-Effectiveness Analysis Registry with data measuring test characteristics and reflecting where value analyses may be most needed: (i) tests currently available or in advanced development, (ii) tests for drugs with Food and Drug Administration labels with genetic information, (iii) tests with demonstrated or likely clinical utility, (iv) tests for conditions with high mortality, and (v) tests for conditions with high expenditures.
resultsWe identified 59 cost-utility analyses studies that examined personalized medicine tests (1998-2011). A majority (72%) of the cost/quality-adjusted life year ratios indicate that testing provides better health although at higher cost, with almost half of the ratios falling below $50,000 per quality-adjusted life year gained. One-fifth of the results indicate that tests may save money.
conclusionMany personalized medicine tests have been found to be relatively cost-effective, although fewer have been found to be cost saving, and many available or emerging medicine tests have not been evaluated. More evidence on value will be needed to inform decision making and assessment of genomic priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.